Researchers have identified a gene that increases the risk of a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin.
Vancomycin, used to treat serious and life-threatening bacterial infections, has been known to be a common antibiotic trigger for a severe reaction known as DRESS -- Drug Rash with Eosinophilia and Systemic Symptoms.
The genetic risk factors predisposing specific patients were not known yet.
The new study, led by researchers from the Vanderbilt University in the US, showed that vancomycin triggers DRESS only in people carrying specific variations in human leukocyte antigen (HLA) genes.
DRESS has been characterised by fever, widespread skin rash and internal organ damage.
Routine testing for HLA gene could improve patient safety and reduce unnecessary avoidance of other antibiotics, said the study published in the Journal of Allergy and Clinical Immunology.
Since many patients who develop DRESS are often exposed to multiple antibiotics and other drugs simultaneously, the team used a specific diagnostic test developed in their laboratories called gamma-interferon ELISpot.
ELISpot exposed patients' white blood cells to vancomycin and other concurrently administered antibiotics. This test enabled them to determine which drug was most likely causing DRESS.
"This test will be important in the clinical care of patients starting vancomycin and will prevent mortality and short and long-term complications," said Elizabeth Phillips, researcher at the varsity.
"This observation also represents significant progress as we zero in on the mechanisms of these life-threatening immune-mediated drug reactions," she said.
--IANS
pb/rt/mag/pcj
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
